Business
BioSpectrum Asia
Sanofi strengthens efforts to prevent Chronic Respiratory Diseases in UAE
The Ministry of Health and Prevention (MoHAP) in the UAE has signed a Memorandum of Understanding (MoU) with Sanofi, to promote healthy lifestyles, advance early detection of noncommunicable diseases (NCDs), and address their associated risk factors.
1 min |
BioSpectrum Asia Sep 2025
BioSpectrum Asia
"Despite advances, access to innovative treatments can be limited, particularly for rare cancers"
Specialised in the discovery and development of novel cell signalling small molecules to treat complex medical conditions, Australian life sciences company QBiotics is currently focusing on novel treatments for cancer and debilitating chronic wounds, along with an early-stage antibiotics programme. While the company is known for its lead product, tigilanol tiglate, which is undergoing clinical trials for various cancers, QBiotics is also actively preparing for a potential IPO on the Australian Securities Exchange (ASX) within this calendar year. To find out more about how QBiotics is tackling some of the most pressing and underserved challenges in global health, BioSpectrum Asia spoke to Stephen Doyle, Chief Executive Officer at QBiotics. Edited excerpts;
4 min |
BioSpectrum Asia Sep 2025
BioSpectrum Asia
US FDA announces new PreCheck Programme to boost local drug manufacturing
The US Food and Drug Administration (FDA) has announced PreCheck, a new programme to strengthen the domestic pharmaceutical supply chain by increasing regulatory predictability and facilitating the construction of manufacturing sites in the United States (US).
1 min |
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Pfizer introduces 20-valent Pneumococcal Conjugate Vaccine (PCV20) for adults in India
Pfizer has announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. With broader serotype coverage, Pfizer’s vaccine marks a significant advancement in protection against pneumococcal disease in adults. Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and noninvasive pneumococcal disease. It enables timely and proactive protection for all adults, including those living with chronic conditions.
1 min |
BioSpectrum Asia Sep 2025
BioSpectrum Asia
TVM Capital Healthcare on-boards Dr Su-Lin Chong as Operating Partner in Malaysia
TVM Capital Healthcare, a leading international healthcare private equity firm and operator focused on emerging markets, has announced the appointment of Dr Su-Lin Chong as Operating Partner and Investment Committee member.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
PHC announces exclusive distribution of MaxCyte ExPERT platform in Japan
The Biomedical Division of Japan-based PHC Corporation (PHCbi), a subsidiary of PHC Holdings Corporation (PHCHD), has signed an exclusive agreement with MaxCyte, Inc. to distribute the MaxCyte EXPERT platform in Japan.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Singapore-Korea partnership to apply AI in hair follicle regeneration research
Singapore-based startup NYB.AI and Pnaseer Inc., a startup based in South Korea, have announced a strategic partnership to accelerate the discovery of compounds that promote hair follicle regeneration using artificial intelligence (AI).
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation
India-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in J. B. Chemicals and Pharmaceuticals from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
UK launches multi-billionpound compute roadmap for healthcare and other sectors
Quicker health diagnoses, smarter energy supplies, tackling climate change and improved public service delivery - just some huge potential benefits of the new compute roadmap, launched by Department for Science, Innovation and Technology (DSIT) and UK Research and Innovation (UKRI).
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
WHO recommends injectable lenacapavir for HIV prevention
The World Health Organization (WHO) has released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention, in a landmark policy action that could help reshape the global HIV response.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Epsilon Healthcare appoints Daniel Kaplon as CFO
Australia-based Epsilon Healthcare has announced the appointment of Daniel Kaplon to the role of Chief Financial Officer (CFO).
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
DKSH and Bayer launch strategic partnership across multiple markets in Southeast Asia
DKSH Business Unit Healthcare, a strategic healthcare solutions partner and leading provider of market expansion services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, has announced a partnership with life science company Bayer.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Waters and BD's Biosciences & Diagnostic Solutions business to merge into one
US-based Waters Corporation and BD (Becton, Dickinson and Company) have announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters, creating an innovative life science and diagnostics leader with pioneering technologies and an industry-leading financial outlook.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
New vaccine set for human trials in Nipah outbreak hotspot
A promising vaccine candidate against one of the world's most deadly viruses, Nipah, is ready for testing in mid-stage human trials in Bangladesh, where people now die almost every year in Nipah disease outbreaks.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
IHH Healthcare catalyses clinical research across global network with initial S$5 M fund
Malaysia headquartered IHH Healthcare, a world-leading integrated healthcare provider, has launched a transformative S$5 million (~Rs 34 crore) Research Grant & Innovation Sandbox programme to accelerate clinical research and innovation across its global network.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
APAC building on enough supply network for radiopharmaceuticals
The radiopharmaceutical industry is gaining ground across the Asia-Pacific (APAC) region, as countries not only step up development of novel therapies but also move to secure critical supply chains. From new partnerships to domestic isotope production, let's explore how APAC is building a foothold in this specialised sector.
4 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
The Future Formula: What's Driving Recruitment Innovation in Pharma
The pharmaceutical recruitment process is becoming more organised, strategic, and data-driven, adapting to changing demands and needs.
5 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Restore Medical secures $23 M to advance medical device for heart failure therapy
Restore Medical, a clinical-stage medtech startup based in Israel, developing transcatheter therapies for heart failure, has announced the successful closing of a $23 million Series B financing round.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
PAHO launches dashboard to monitor respiratory viruses in the Americas
The Pan American Health Organization (PAHO) has launched a new interactive dashboard to enhance monitoring and analysis of respiratory virus circulation trends across the Americas, with the goal of strengthening surveillance and facilitating timely analysis of regional trends.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
HanchorBio signs $200 M deal with Shanghai Henlius Biotech to expand immuno-oncology reach
HanchorBio Inc., a Taiwan-based biotechnology startup developing innovative immunotherapies for oncology and autoimmune diseases, has announced the signing of a major out-licensing agreement with Shanghai Henlius Biotech, Inc.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Resurging Funding Catapults APAC BIOTECH STARTUPS
Asia-Pacific's biotech startup scene is on the cusp of a renaissance. After a tough 2024 marked by shrinking venture capital, 2025 is showing revived investor enthusiasm and a rebound in funding- especially for oncology, gene therapy, and AI-driven drug discovery. With 9,905 life sciences startups now active across the region, APAC Countries are leveraging scientific innovation, government support, and new incubators to move beyond service roles and develop world-class therapeutic assets. Let's take a closer look at Asia's startup ecosystem, evolution of investor sentiment over the past few years, and buoying biotech areas.
10 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
WHO maps application of AI in traditional medicine
In a significant milestone for global healthcare innovation, the World Health Organization (WHO) has released a technical brief titled \"Mapping the Application of Artificial Intelligence in Traditional Medicine\", acknowledging India’s pioneering efforts in integrating Artificial Intelligence (AI) with traditional medicine systems, particularly Ayush systems.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Thermo Fisher introduces new assay to help advance future of precision medicine
US-based Thermo Fisher Scientific has announced that the Oncomine Comprehensive Assay Plus is now available on the Ion Torrent Genexus System helping accelerate precision oncology research.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Agilent launches InfinityLab Pro iQ Series Mass Detectors in India
Agilent Technologies has launched its InfinityLab Pro iQ Series mass detectors in India.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Chugai and Gero ink $250 M deal to develop new therapies for age-related diseases
Japan's Chugai Pharmaceutical and Gero, a Singaporebased biotechnology company, have entered into a joint research and license agreement to develop novel therapies for age-related diseases.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Emergency vaccine response cuts infectious disease deaths by nearly 60%
Researchers at Burnet Institute, in collaboration with Gavi, the Vaccine Alliance, have provided the world's first ever look at the historical impact of emergency vaccination efforts on public health and global health security, with a comprehensive study of 210 outbreaks of five infectious diseases- cholera, ebola, measles, meningitis and yellow fever, in 49 lower-income countries between 2000 and 2023.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
“We plan to enter India, Japan, Thailand, and Vietnam to improve the safety of researchers”
As biotech research laboratories, in both industry and academic settings, engage in increasingly complex projects worldwide, ensuring the safety of personnel, equipment, and the surrounding environment becomes paramount.
4 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
JCR Pharma licenses gene therapy platform to AstraZeneca Rare Disease unit for $825 M
Japan's JCR Pharmaceuticals has entered into a license agreement with Alexion, AstraZeneca Rare Disease, for JCR's new, proprietary JUST-AAV capsids to develop genomic medicines.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Hong Kong launches generelated therapy trials to eradicate chronic hepatitis B infection
Researchers in gastroenterology and hepatology at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), have initiated multiple clinical trials exploring pioneering generelated therapy for chronic hepatitis B infection, potentially allowing patients to discontinue long-term medication.
1 min |
BioSpectrum Asia August 2025
BioSpectrum Asia
Wuxi Biologics launches next-generation platform for high-concentration biologics
Wuxi Biologics, a leading global Contract Research, Development, and Manufacturing Organisation (CRDMO) in China, has announced the launch of WuXiHigh 2.0, a high-throughput formulation development platform designed for high concentration biologics.
1 min |